Histone Deacetylase 10-inhibitor Co-Treatment in Cancer
Histone deacetylase inhibitors (HDACi) are prom-ising anticancer agents and are currently being evaluated in clinical trials. However, due to their unselective action, pan-HDACi exhibit dose-limiting side-effects restricting their full potential in anti-cancer therapy. Therefore, characterization of the molecular function of single HDAC isozymes is of major importance for a targeted therapy with less side-effects.
Further Information: PDF
DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
Media Contact
All latest news from the category: Technology Offerings
Newest articles

Using Electroencephalography to Improve Language Disorder Treatments
Researchers work towards an inexpensive and portable solution for treating aphasia Electroencephalography (EEG) may offer a more accessible alternative to functional magnetic resonance imaging (fMRI) for guiding transcranial direct current…

Measuring Life on Earth from Space: A Global Research Project
Measurements and data collected from space can be used to better understand life on Earth. An ambitious, multinational research project funded by NASA and co-led by UC Merced civil and…

Best Approach for Stroke in Medium-Sized Blood Vessels Identified
Calgary’s Stroke Program advancing science to improve care, treatment and outcomes for patients University of Calgary’s Hotchkiss Brain Institute researchers with the Calgary Stroke Program at Foothills Medical Centre revolutionized…